Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 14/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.47 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5358065 | 0.90 | DPP4 (0.47) | DPP4CHRM1HTR3A | |
| SCHEMBL13217900 | 0.86 | DPP4 (0.50) | DPP4CHRM1HTR3A | |
| SCHEMBL5359407 | 0.86 | DPP4 (0.45) | DPP4CHRM1HTR3A | |
| SCHEMBL2964587 | 0.84 | DPP4 (0.66) | DPP4CHRM1 | |
| SCHEMBL5359364 | 0.84 | DPP4 (0.49) | DPP4CHRM1 | |
| SCHEMBL5359244 | 0.84 | DPP4 (0.44) | DPP4CHRM1MRGPRX1 | |
| SCHEMBL5362098 | 0.83 | DPP4 (0.45) | DPP4CHRM1MRGPRX1 | |
| SCHEMBL5353926 | 0.83 | DPP4 (0.43) | DPP4CHRM1HTR6 | |
| SCHEMBL5360456 | 0.81 | DPP4 (0.46) | DPP4CHRM1HTR3A | |
| SCHEMBL5354884 | 0.81 | DPP4 (0.50) | DPP4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217711-B2 | Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-15 | — | — | US | claimed |
| US-20050171093-A1 | New piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutial compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-08-04 | — | — | US | claimed |
| US-7217711-B2 | Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171093-A1 | New piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutial compositions | DPP4, DPP3, DPP7 | DPP4 1/4885CHRM1 515/4885MRGPRX1 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.